The FDA is warning healthcare providers of dosing errors associated with compounded versions of semaglutide, the active ingredient in Ozempic, Rybelsus and Wegovy.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
FDA warns of dosing errors tied to compounded Ozempic, Wegovy
